scholarly journals Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3462
Author(s):  
Cristiane Fonseca de Almeida ◽  
Paula Simplicio da Silva ◽  
Claudia Santos de Aguiar Cardoso ◽  
Nathalia Gorni Moreira ◽  
Julliana Cormack Antunes ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Protective Factor ◽  
Hiv Care ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Total Fat

We aimed to evaluate the relationship between food intake of lipids with nonalcoholic fatty liver disease (NAFLD) and/or liver fibrosis in people living with HIV/AIDS (PLWHA). In this cross-sectional study, transient elastography was used to detect the presence of NAFLD and/or liver fibrosis. The dietary intake of fats and fatty acids (FA) were assessed by two 24 h dietary recalls (24-HDR) (n = 451). Multivariate logistic regression models were performed. Participants with higher intake of total fat were associated with higher odds for NAFLD compared to those with lower consumption [adjusted odds ratio (aOR) = 1.91 (95% confidence interval (95% CI) 1.06–3.44)]. Furthermore, participants with intermediate intake of n6-PUFA (n6-poly-unsaturated FA) and lauric FA had lower odds for NAFLD, respectively aOR = 0.54 (95% CI 0.3–0.98) and aOR = 0.42 (95% CI 0.22–0.78). Additionally, a higher intake of myristoleic FA (fourth quartile) was a significant protective factor for NAFLD [aOR = 0.56 (95% CI 0.32–0.99)]. Participants with higher intake of lauric FA [0.38 (95% CI 0.18–0.80)], myristic FA [0.38 (0.17–0.89)], palmitoleic FA [0.40 (0.19–0.82)] and oleic FA [0.35 (0.16–0.79)] had positively less odds of having liver fibrosis. On the other hand, higher intake of n-6 PUFA was significantly associated with fibrosis [aOR = 2.45 (95% CI 1.12–5.32)]. Dietary assessment of total fat and FA should be incorporated into HIV care as a tool for preventing NAFLD and fibrosis in PLWHA.

scholarly journals Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes

JGH Open ◽  
2021 ◽  
Author(s):  
Mohammad Shafi Kuchay ◽  
Narendra Singh Choudhary ◽  
Sunil Kumar Mishra ◽  
Tarannum Bano ◽  
Sakshi Gagneja ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

M1988 Noninvasive Markers of Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease (NAFLD)

2010 ◽  
Vol 138 (5) ◽  
pp. S-453 ◽  
Author(s):  
Naim Alkhouri ◽  
Christine A. Carter-Kent ◽  
Anna Alisi ◽  
Ariel E. Feldstein ◽  
Valerio Nobili
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Noninvasive Markers

scholarly journals Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

Hepatology ◽  
2010 ◽  
Vol 51 (4) ◽  
pp. 1209-1217 ◽  
Author(s):  
Luca Valenti ◽  
Ahmad Al-Serri ◽  
Ann K. Daly ◽  
Enrico Galmozzi ◽  
Raffaela Rametta ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

scholarly journals The “GG” genotype of rs26802 variant in the ghrelin gene is a potential protective factor against nonalcoholic fatty liver disease

2021 ◽  
Author(s):  
Gholamreza Rezamand ◽  
Touraj Mahmoudi ◽  
Seidamir Pasha Tabaeian ◽  
Hamid Farahani ◽  
Fatemeh Shahinmehr ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Protective Factor ◽  
Nucleotide Polymorphisms ◽  
Nonalcoholic Fatty Liver ◽  
Ghrelin Receptor ◽  
Significant Difference ◽  
Ghrelin Gene

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is an emerging global chronic liver disease worldwide. Considering the powerful association between NAFLD, insulin resistance (IR) and obesity, as well as the key role of ghrelin in these metabolic disorders, we hypothesized that some single nucleotide polymorphisms (SNPs) of the ghrelin (GHRL) and ghrelin receptor (GHSR) genes might be associated with NAFLD. Methods We conducted a case-control retrospective study of 150 cases with biopsy-proven NAFLD and 155 controls. The diagnosis of NAFLD was established before the start of the genotyping process. All the 305 subjects were genotyped for GHRL SNP rs26802 or -501T>G and GHSR SNP rs572169 or Arg159Arg using the PCR-RFLP method. Results The GHRL rs26802 “GG” genotype compared with the “TT” genotype and “TT+TG” genotype appears to be a marker of decreased NAFLD susceptibility even after adjustment for confounding factors (P = 0.006; OR = 0.14, 95% CI = 0.03–0.56 and P = 0.003; OR = 0.16, 95% CI = 0.05–0.53, respectively). However, we observed no significant difference in genotype or allele frequencies between the cases and controls for GHSR SNP rs572169. Conclusions These findings proposed, for the first time, that the GHRL rs26802 “GG” genotype has a protective effect against NAFLD. Nonetheless, this observation warrants further investigations in other populations.

scholarly journals Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease

2017 ◽  
Vol 51 (3) ◽  
pp. 188-195 ◽  
Author(s):  
Yu.M. Stepanov ◽  
N.V. Nedzvetskaya ◽  
V.B. Yagmur ◽  
I.A. Klenina ◽  
N.Yu. Oshmyanskaya
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Noninvasive Diagnosis ◽  
Nonalcoholic Fatty Liver

Emerging prevalence of fatty liver disease in HIV

2021 ◽  
Vol 16 (1) ◽  
pp. 59-73
Author(s):  
Amreen Dinani ◽  
Ali Khan ◽  
Douglas Dieterich
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Unmet Need ◽  
Hiv Care ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Infected People ◽  
Direct Acting ◽  
Living With Hiv

Fatty liver disease is a growing concern in people living with HIV, the main drivers are alcoholic liver disease and nonalcoholic fatty liver disease. It has shown to negatively impact HIV care continuum and result in notable non-HIV related morbidity and mortality. With the advancement in antiretroviral therapy and effective direct acting antivirals, fatty liver disease is surfacing as the next big challenge in this population like that observed in the general population. This review article summarizes the gravity of these two common diseases in HIV-infected people and aims to sheds light on an unmet need to develop effective methods to identify, screen and manage fatty liver disease in this unique population.

Sign in / Sign up

Export Citation Format

Share Document